Semaglutide for adults living with obesity
Review (18 RCTs, n=27,949) found semaglutide results in a clinically relevant weight loss at medium‐term follow‐up vs placebo, likely to be sustained in long term while on treatment. Effects on quality of life, major adverse CV events & mortality are likely limited or uncertain.
Source:
Cochrane Database of Systematic Reviews
Further information:
Cochrane reviews of tirzepatide and liraglutide for adults living with obesity have also been published.